文献速递精神分裂症与精神病性障碍物质与行为成瘾

大麻素CB1受体偏向性信号作为精神分裂症治疗靶点的展望

Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.
PubMed 文献 · Am J Psychiatry · 2026-04-17

本文综述内源性大麻素系统与精神分裂症症状的关系,指出大麻使用与精神分裂症存在共享遗传风险且大麻可剂量依赖性增加患病风险、急性加重症状并恶化长期预后。Δ9-四氢大麻酚靶向CB1受体,作者总结CB1受体皮层生物学与性别差异、精神分裂症中CB1受体改变及合并大麻使用的影响、细胞类型特异性发现和GPCR偏向性配体药理学进展,提出CB1受体靶向治疗精神分裂症的未来方向。

要点

  • 大麻使用剂量依赖性增加精神分裂症诊断可能性并急性加重症状、恶化长期预后。
  • 精神分裂症患者大麻使用率远高于一般人群,共享遗传风险可部分解释此现象。
  • CB1受体细胞类型特异性发现与GPCR偏向性配体进展为靶向治疗提供新机会。

核心结论

  • 基于对CB1受体更细致的理解,作者提出有望开发针对精神分裂症的CB1受体靶向治疗,尤其适用于合并大麻使用的患者。

研究设计与样本

  • 本文为简述性综述,聚焦CB1受体作为精神分裂症治疗靶点的近期进展,未报告系统检索范围。

主要发现

  • 大麻使用剂量依赖性增加获得精神分裂症诊断的可能性,并急性加重精神分裂症症状、恶化患者长期预后。
  • 精神分裂症患者使用大麻的比例远高于一般人群,共享遗传风险可部分解释该现象。
  • Δ9-四氢大麻酚靶向G蛋白偶联受体CB1受体。
  • 综述涵盖CB1受体皮层生物学与性别差异、精神分裂症中CB1受体改变及合并大麻使用的影响、细胞类型特异性发现和GPCR偏向性配体药理学进展。

临床怎么用

  • 临床应关注精神分裂症患者的大麻使用,因其可剂量依赖性增加诊断可能性、急性加重症状并恶化长期预后。
  • CB1受体偏向性信号为开发精神分裂症靶向治疗提供潜在方向,尤其针对合并大麻使用的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The relationship between the endocannabinoid system and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant interest within psychiatry. Cannabis is the most widely used recreational drug worldwide, and individuals with schizophrenia use it at a much higher rate than the general population. The shared genetic risk for schizophrenia and cannabis use may partially account for this phenomenon. However, the exposure to cannabis in individuals at risk of schizophrenia appears to not only represent the manifestation of overlapping risks, but also pharmacological exacerbation of an already altered cortical system. Thus, cannabis use dose-dependently increases the likelihood of receiving a schizophrenia diagnosis, acutely exacerbates schizophrenia symptoms, and worsens long-term prognosis for individuals with schizophrenia. The psychoactive substance in cannabis, Δ9-tetrahydrocannabinol, targets the cannabinoid CB1 receptor (CB1R), a G protein-coupled receptor (GPCR). This brief review focuses on recent advances that may enable effective therapeutic targeting of CB1R for the treatment of schizophrenia, especially in individuals with comorbid schizophrenia and cannabis use. The authors summarize the current understanding of CB1R relevant to schizophrenia in sections covering the basic cortical biology and sex differences of CB1R; current knowledge of CB1R alterations in schizophrenia and the potential impact of comorbid cannabis use; recent cell type-specific findings that reconcile past discrepant research in the field; and advances in understanding of GPCR pharmacology and biased ligands that provide new opportunities for CB1R-targeted therapeutics. Derived from this more nuanced understanding of CB1R, the authors propose future directions with the potential to develop a CB1R-targeted treatment of schizophrenia.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ku SH, Stringfield SJ, Torregrossa MM, et al. Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia. Am J Psychiatry. 2026. PMID: 41992094. doi:10.1176/appi.ajp.20250886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。